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The most important prognostic factor in the management
of head and neck cancer is the presence of cervical nodal
metastasis. Once the tumor involves neck nodes, survival
drops by almost 50%. Management of cervical metastasis
has gone through an evolution since the beginning of the
last century. The classic radical neck dissection, where all
the neck nodes are removed along with 3 important struc-
tures – sternocleidomastoid muscle, internal jugular vein
and accessory nerve – was popularized in the landmark
article by George Crile. It subsequently became the stand-
ard of care in the management of neck nodes for almost
75 years.
The major complication from radical neck dissection was
very apparent to most clinicians; shoulder dysfunction,
which led to modifications in neck dissection techniques.
Oswaldo Suarez gets the credit for popularizing func-
tional neck dissection wherein the accessory nerve is care-
fully preserved to the extent tumor involvement allows.
He also popularized the facial envelope and oncologic
safety of modified neck dissection, which gained accept-
ance with the teachings of Itore Bocca, Javier Gavilan, and
Richard Jesse. In the 1980's there was a tremendous switch
from radical neck dissection to modified neck dissection
to maintain patient quality of life and preserve shoulder
function. At the same time, the patterns of nodal metasta-
sis were studied in detail. Publications from Lindberg and
Shah described the location of metastatic disease in the
neck depending upon the primary site, and justified mod-
ifications in neck dissection [1]. By the mid 1980's there
was confusion and disagreement about the nomenclature
of various modifications, and every institution had their
own modification. In an effort to standardize the nomen-
clature, the American Academy of Otolaryngology-Head
and Neck Surgery developed a systematic approach to
neck dissection, dividing it into comprehensive and selec-
tive neck dissections [2,3].
In the recent modification of the standardization of neck
dissection, the Committee on Head and Neck Oncology
divided Levels I, II and V into A&B groups [3]. This divi-
sion appears to be anatomically sound in relation to met-
astatic disease to the neck. For example, Level IA is rarely
involved in metastatic disease. At the same time, Level IIB
nodes are rarely involved in metastatic tumor unless there
is a bulky metastatic disease at Level II. One may consider
super-selective neck dissections. There appears to be a
trend in deleting specific names for the modification of
neck dissection and use selective neck dissections with the
structures and group of lymph nodes removed as specific
types.
The comprehensive neck dissection removes all lymph
nodes in the neck and its modification includes preserva-
tion of the sternocleidomastoid muscle, accessory nerve
or jugular vein. The selective neck dissection addresses a
select group of lymph nodes based on the location of the
highest incidence of metastatic disease, thus supraomohy-
oid neck dissection became very popular as a staging pro-
cedure for cancer of the oral cavity [4]. Interest developed
in understanding the prognostic factors of metastatic dis-
ease in the neck, such as tumor size, location, and extran-
odal spread.
Postoperative radiation therapy in patients with cervical
neck node metastasis became the standard practice in the
early 1990's. The high incidence of metastatic disease to
neck nodes from cancer of the oral tongue was noted at
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the same time. Supraomohyoid neck dissection became
standard practice in patients with cancer of the oral cavity
and N0 neck.
Clinical evaluation was supplemented with imaging stud-
ies, such as computerized tomography (CT) and magnetic
resonance imaging (MRI) scanning. Van den Brekel from
Amsterdam popularized the role of ultrasound and ultra-
sound-guided needle biopsy [5]. Even though the
researchers from Amsterdam reported excellent correla-
tion, ultrasound did not become very popular in day-to-
day clinical surgical practice. It does play an important
role in the initial evaluation of cervical metastasis and in
patient follow-up, particularly in those who have received
chemo-radiation therapy. Ultrasound is an easy outpa-
tient test which can be performed at frequent intervals
during follow-up. In the mid 1990's an interest developed
in using PET scanning to diagnose neck metastasis. Even
though PET scanning can be a useful tool, particularly
FDG uptake evaluation, it has not helped to make clini-
cally definitive decisions as to the presence or absence of
metastatic disease. Small volume disease, especially in the
N0 neck, is difficult to image with a PET scan. PET scan-
ning appears to be an important investigative tool in
patients who are being followed after nonsurgical treat-
ment, such as chemo-radiation therapy. Further studies
are necessary, however, to standardize the SUV (Standard
Uptake Value) in the PET scan.
Postoperative radiation therapy was routinely recom-
mended in patients with large nodal metastasis and
extranodal spread. Extranodal spread was considered to
indicate grave prognosis in patients with cervical metasta-
sis. These patients had a high incidence of local recurrence
and distant metastasis. With this in mind, the EORTC and
RTOG conducted randomized prospective trials of the use
of postoperative chemo-radiation therapy in patients with
cervical nodal metastasis. It is interesting that the two
groups reported their results in the same issue of the New
England Journal of Medicine.
Cooper, et al, [6] from the Radiation Therapy Oncology
Group reported results from a randomized prospective
trial in the New England Journal of Medicine. There were
231 patients randomly assigned to receive postoperative
radiation therapy alone, and 228 patients to receive iden-
tical treatment plus concurrent chemotherapy with cis-
platinum 100 mg per m2 on days 1, 22 and 43. They
reported the estimated 2 year rate of local and regional
control as 82% in the combined therapy group, as com-
pared with 72% in the radiotherapy alone group. Disease-
free survival was significantly longer in the combined
therapy group than in the radiotherapy group; however,
interestingly the overall survival was not altered by the
addition of chemotherapy. The incidence of acute adverse
effects of Grade III or greater was reported in 34% of the
radiotherapy group and 77% in the combined therapy
group. Four patients who received combined therapy died
as a direct result of treatment. The authors concluded that
among high risk patients in the postoperative setting, con-
current chemo-radiation therapy significantly improves
the rates of local and regional control and disease-free sur-
vival. However, the combined treatment is associated with
a substantial increase in adverse effects.
In the same issue of the New England Journal of Medicine,
Bernier et al, [7] reported on the European Organization
for Research and Treatment Cancer Trial 22931. They ran-
domly assigned 167 patients in each group to receive post-
operative radiation therapy or radiation and
chemotherapy. They also used 100 mg cisplatinum per m2
on days 1, 22 and 43 of the radiotherapy regimen. They
reported a 5 year progression-free survival of 47% com-
pared to 36% with radiation therapy alone. They reported
an overall survival rate of 53% in patients who received
chemo-radiation therapy compared to 40% with radia-
tion therapy alone. The estimated 5-year cumulative inci-
dence of local or regional relapses was 31% after
radiotherapy and 18% after combined therapy. This group
also reported severe adverse effects from combined ther-
apy (41%) and radiotherapy alone (21%).
Even though these two studies are prospective rand-
omized trials, further confirmation needs to be obtained
through continued interest in such trials including reduc-
tion of adverse effects. The most important complication
of combined chemo-radiation therapy that has been
noted in organ preservation protocols is severe mucositis
and pharyngeal stricture. Pharyngeal stricture is a disas-
trous complication from this treatment and has a major
impact on the quality of life of the patients.
It appears that in patients with poor prognostic factors
with cervical metastasis there is an increasing interest in
treatment with chemo-radiation therapy, rather than radi-
ation alone. Obviously one needs to keep in mind the
complications related to chemo-radiation therapy. Such
complications are well recognized in patients who
undergo an organ preservation protocol for laryngopha-
ryngeal tumors or for oropharyngeal cancers. There is a
high incidence of neutropenia, Grade 4 mucositis, and
pharyngeal stricture. Development of pharyngeal stricture
continues to be a difficult problem to manage in clinical
practice and leads to discussion regarding the quality of
life. Long term dependency on gastrostomy is extremely
frustrating to patients who may have been cured of their
neck disease. Since organ preservation and chemo-radia-
tion therapy has become the most prevalent treatment for
patients with oropharyngeal and laryngopharyngeal can-
cers, it has generated controversy about the managementPublish with BioMed Central    and   every 
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of patients with nodal metastasis and their follow-up. The
general consensus of opinion is that N1 disease can be
easily controlled with chemo-radiation therapy. The prob-
lem comes with patients who present with N2 and N3
neck disease. Even though approximately 50% of the
patients can be cured with chemo-radiation therapy, the
remaining patients may persist with microscopic nodal
metastasis. Even though there is no unanimous consensus
today about how to manage N2–N3 neck after chemo-
radiation therapy, there appears to be a general trend to
consider close follow-up of these patients with clinical
exam, CT, MRI and PET scan. If there is a residual thicken-
ing or presence of nodal disease, neck dissection is rou-
tinely recommended. Approximately 40–50% of patients
may have viable tumor, which also depends upon the
location of the primary tumor.
The patients who recur in their neck nodes after previous
surgery and radiation therapy are clearly a major chal-
lenge to the head and neck surgeon. Every attempt is made
to resect the tumor if that is possible, along with (in select
patients) additional local radiation therapy or brachyther-
apy. If brachy catheters are to be used, the carotid artery
needs additional protection, preferably with myocutane-
ous flaps. Carotid resection is considered in very select cir-
cumstances where the patient has satisfactory carotid
blood flow from the opposite side, and appropriate recon-
struction is considered with carotid replacement by either
a gortex graft or saphenous vein. There is a high incidence
of neurologic complications when the carotid artery is
resected. One needs to keep in mind that the carotid artery
may not be the only limiting factor in such patients with
metastatic disease to the neck. The surrounding structures,
such as the vagus nerve, sympathetic trunk, and scalene
muscles are also directly involved by the tumor. An appro-
priate and satisfactory surgical resection should be under-
taken only if possible.
With increasing interest in sentinel node biopsy in
melanoma and breast cancer, some investigators have
extended this technology to the squamous carcinoma of
the upper aerodigestive tract, especially cancer of the oral
cavity [8]. The American College of Surgeons Oncology
Group has launched a prospective study of sentinel node
biopsy in tumors of the oral cavity. At this stage, the sen-
tinel node biopsy should be used only as an investiga-
tional tool.
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